Paradigm Health has completed the acquisition of Flatiron Health’s clinical research business shortly after successfully raising $78 million in a Series B financing round.

Network Expansion and Reach

• Network Growth: With the acquisition, Paradigm’s network has expanded to encompass more than 25 medical centers and nearly 100 community oncology practices across the United States.

• Customer Base: The enlarged network now enables Paradigm to serve 15 of the top 20 global biopharma companies.

• Trial Capacity: Paradigm CEO Kent Thoelke framed the deal as a major step toward “accelerating our impact in the US so that more trials can happen where patients actually receive care,” and adds capacity to run pragmatically designed Phase IV trials.

Technology Collaboration and AI Integration

Although the financial terms of the acquisition were not disclosed, the two companies have agreed to a long-term technology collaboration.

• AI Integration: The plan involves integrating Paradigm’s AI technology into Flatiron’s clinical trial management software.

• Vision: Flatiron CEO Nathan Hubbard noted that combining Paradigm’s AI-powered infrastructure with Flatiron’s established network creates a “stronger, more connected ecosystem for clinical research,” accelerating impact and advancing the shared mission “to bring new treatments to patients faster.”

The $78 million in Series B funding is intended to fuel this network expansion, particularly targeting underserved community markets.

Source: https://www.bioxconomy.com/clinical-and-research/untitled

The American pharmaceutical giant, Eli Lilly, has designated Huntsville, Alabama, as the location for its third manufacturing facility dedicated to Orforglipron. This facility is integrated into the company’s comprehensive pledge to invest $27 billion in expanding its pharmaceutical manufacturing footprint across the United States.

• Scope and Timeline: The Alabama project is valued at $6 billion and is scheduled to begin construction in 2026.

• Job Creation: The site is expected to generate 3,000 roles during the construction phase and over 450 skilled jobs, including scientists, engineers, and lab technicians, upon its opening.

• Production Focus: The new site will manufacture synthetic small molecule and peptide medicines, with a particular focus on Orforglipron—the newest potential addition to the company’s arsenal of Glucagon-like Peptide Receptor Agonists (GLP-1RA).

To optimize operations, Eli Lilly plans to integrate advanced technologies such as Machine Learning (ML), Artificial Intelligence (AI), and digital automation to streamline processes and secure the supply chain.

Wider Global Expansion Context

The Alabama facility falls under Eli Lilly’s strategy of US onshoring. As part of this $27 billion drive, Lilly is constructing four new sites in the US, including:

• A $6.5 billion Orforglipron manufacturing site in Texas.

• A $1.2 billion investment to expand its existing Orforglipron production facility in Puerto Rico.

• A $5 billion facility in Virginia for the production of Monoclonal Antibodies (mAbs) and Bioconjugates.

In addition, the company is strengthening its European manufacturing presence by developing a new $3 billionOrforglipron facility in the Netherlands and undertaking a $1 billion expansion of its site in Limerick, Ireland.

This aggressive US expansion comes amid threats from the Trump administration to impose 100% tariffs on branded pharmaceuticals unless companies are “breaking ground” on a US manufacturing facility.

Growth Outlook

The manufacturing scale-up occurs while Eli Lilly is experiencing immense growth, having recently joined the $1 trillion market cap club.

This business boom is primarily fueled by its successful obesity and type 2 diabetes (T2D) portfolio, featuring best-sellers like Zepbound and Mounjaro (tirzepatide).

With the company preparing to submit a New Drug Application (NDA) for Orforglipron to the FDA, the drug is projected to launch in 2026. Analysts predict that Orforglipron could become a mega-blockbuster, potentially generating $13 billion in annual sales by 2031. However, Eli Lilly is expected to face competition from rival Novo Nordisk in the oral GLP-1RA category, particularly with the pending FDA decision on oral Semaglutide (Wegovy) for weight loss.

Relation Therapeutics has announced the formation of a multi-program, strategic alliance with Novartis with the aim of accelerating the development of therapeutic solutions for atopic diseases.

Atopic diseases, a group of allergic conditions including asthma, allergies, and eczema, are characterized by immune dysregulation.

Technological Integration

• The collaboration merges Relation’s AI-powered drug discovery platform, known as the “Lab-in-the-Loop,”with Novartis’s established expertise in immuno-dermatology.

• Relation’s platform integrates AI with patient-derived multi-omic data and proprietary experimental systems to potentially uncover causal genes and refine target hypotheses.

• Relation is slated to lead observational studies that will generate functional cell atlases directly from human patient tissue. This rigorous approach is intended to maximize the chance of identifying successful targets before candidates enter the clinical phase.

• The core objective is to identify, validate, and advance potential first-in-class therapeutic targets for these immune-driven atopic conditions.

• Novartis secures worldwide development and commercialization rights to any resulting drug targets identified through the partnership.

Financial Structure

• Relation is set to receive an initial total payment of $55 million, which includes an upfront payment, an equity investment, and supplemental Research & Development (R&D) funding.

• Furthermore, Relation is eligible to receive preclinical, development, regulatory, and commercial sales milestone payments potentially reaching over $1.7 billion.

• The company is also entitled to receive tiered royalties on net sales of any resulting commercialized products.

Executive Statements

• Relation’s Chief Executive Officer stated that their technology helps define molecular pathways in diseased versus healthy tissue, supporting the discovery of new therapeutics. He expressed that the combination with Novartis’s development and commercialization capabilities could potentially deliver medicines capable of transforming the standard of care.

• The President of Biomedical Research at Novartis affirmed the company’s commitment to leveraging cutting-edge, AI-driven approaches to enhance novel target identification and accelerate the drug discovery process.

Source: https://www.fiercebiotech.com/biotech/novartis-pens-17b-dermatology-pact-ai-enabled-british-biotech

Licensing Agreement Details

• Pfizer, the U.S.-based pharmaceutical manufacturer, has signed an exclusive licensing deal with Yao Pharma—a subsidiary of Fosun Pharmaceutical—to secure worldwide development and commercialization rights to a GLP-1 receptor agonist known as YP05002, and any other related GLP-1 agonists under Yao Pharma’s development.

• Pfizer is providing an upfront payment of $150 million to Yao Pharma.

• Yao Pharma stands to receive further development, regulatory, and commercial milestone payments potentially reaching up to $1.93 billion, in addition to tiered royalties on net sales.

• The agreement allows Yao Pharma to complete the ongoing Phase 1 weight management study for YP05002 currently underway in Australia.

YP05002 and Pipeline Strategy

• YP05002 is a small-molecule GLP-1 agonist that Yao Pharma has indicated has therapeutic potential beyond weight loss, including in conditions such as diabetes and metabolic dysfunction-associated steatohepatitis (MASH).

• Pfizer’s strategy includes evaluating YP05002 in combination with its GIPR antagonist, PF-07976016, as well as other small molecules within its development pipeline.

• This transaction follows Pfizer’s recent effort to rebuild its obesity portfolio after discontinuing three previous GLP-1 candidates due to issues such as elevated liver enzymes or insufficient Phase 1 data.

• Recently, Pfizer also successfully secured the ownership of GLP-1 biotechnology company Metsera after a surprise bidding conflict, adding Metsera’s injectable asset, MET-097i (which is in Phase 2b testing and has the potential for once-a-month dosing), to its portfolio.

Strategic Vision

• Chris Boshoff, M.D., Ph.D., Pfizer’s Chief Scientific Officer, reaffirmed that cardiometabolic research is a “strategic priority” expected to be a key driver of growth for the company.

• Dr. Boshoff stated that Pfizer looks forward to contributing its expertise to continue the development of this investigational GLP-1 small molecule, noting that it “complements and strengthens” the company’s growing portfolio of novel candidates for treating obesity and related diseases.

• Liu Qiang, Chairman of Yao Pharma, viewed the partnership as an international recognition of Yao Pharma’s R&D capabilities. He expressed that leveraging Pfizer’s global development experience and commercial network, combined with Yao Pharma’s expertise, will enable the innovative drug candidate to be developed and commercialized more quickly and broadly for the benefit of patients worldwide.

Source: https://www.fiercebiotech.com/biotech/pfizer-continues-renewed-obesity-push-2b-pact-fosun-units-glp-1-drug

Relation Therapeutics has announced the formation of a multi-program, strategic alliance with Novartis with the aim of accelerating the development of therapeutic solutions for atopic diseases.

Atopic diseases, a group of allergic conditions including asthma, allergies, and eczema, are caused by immune dysregulation, leading to IgE antibodies overreacting to allergy triggers.

Technological Integration

• The collaboration merges Relation’s AI-powered drug discovery platform, known as “Lab-in-the-Loop,” with Novartis’s established expertise in immuno-dermatology.

• The “Lab-in-the-Loop” platform integrates AI with patient-derived multi-omic data and proprietary experimental systems to potentially uncover causal genes and refine target hypotheses.

• The primary objective is to identify, validate, and advance potential first-in-class therapeutic targets for these immune-driven atopic conditions.

• Under the agreement, Relation is slated to lead observational studies to generate functional cell atlases directly from human patient tissue, an approach expected to mitigate the risk of clinical failure.

• Novartis secures worldwide development and commercialization rights to any resulting drug targets identified through the partnership.

Financial Structure

• Relation is set to receive an initial total payment of $55 million, which includes an upfront payment, an equity investment, and supplemental Research & Development (R&D) funding.

• Furthermore, Relation is eligible to receive preclinical, development, regulatory, and commercial sales milestone payments potentially reaching over $1.7 billion.

• The company is also entitled to receive tiered royalties on net sales of any resulting commercialized products.

Executive Statements

• Relation’s Chief Executive Officer stated that their technology helps define molecular pathways in diseased versus healthy tissue, supporting the discovery of new therapeutics. He expressed belief that, combined with Novartis’s development and commercialization capabilities, they can deliver medicines capable of transforming the standard of care.

• The President of Biomedical Research at Novartis affirmed the company’s commitment to leveraging cutting-edge, AI-driven approaches to enhance novel target identification and accelerate the drug discovery process, delivering innovative medicines for patients in need.

On December 9, 2025, a major pharmaceutical corporation based in New York announced it had entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited.

The agreement focuses on the development, manufacturing, and commercialization of YP05002. YP05002 is a small molecule that acts as a glucagon-like peptide 1 (GLP-1) receptor agonist, currently in Phase 1 trials for chronic weight management.

Under the disclosed terms, YaoPharma will complete the ongoing Phase 1 clinical trial for YP05002. Following this, the major pharmaceutical company will be granted an exclusive license to further develop, manufacture, and commercialize this drug candidate globally.

Financially, YaoPharma will receive an upfront payment of $150 million. Additionally, the company is eligible to receive milestone payments associated with development, regulatory, and commercial achievements, totaling up to $1.935 billion, along with tiered royalties on sales if the product is approved.

This action reinforces the pharmaceutical group’s efforts to advance investigational medicines for cardiometabolic diseases. A senior executive emphasized that cardiometabolic research is a strategic priority with the potential to be a key driver of growth for the business.

Future plans for the corporation include conducting combination studies of YP05002 with their glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist candidate, currently in Phase 2, as well as with other small molecules within its development pipeline.

Source: https://www.businesswire.com/news/home/20251209536063/en/Pfizer-Enters-into-Exclusive-Collaboration-and-License-Agreement-with-YaoPharma

(ASH Congress) – AstraZeneca (AZ) announced positive clinical data for its leading cell therapy candidate, AZD0120 (formerly GC012F), for the treatment of relapsed/refractory multiple myeloma at this year’s American Society of Hematology (ASH) conference.

AZD0120 is a CAR-T (Chimeric Antigen Receptor T-cell) therapy designed to dual-target both BCMA and CD19antigens. The therapy was acquired by AZ through its purchase of Chinese biotech Gracell in 2024.

DURGA-1 Trial Results

The Phase 1b/2 DURGA-1 study was an open-label, single-arm trial conducted in US patients, some of whom had previously received anti-BCMA treatment.

• Objective Response Rate (ORR): Achieved 96%.

• Combined Complete Response (CR) and stringent CR (sCR) rate: Reached 78.3%.

• The median time to response was a rapid 28 days.

• These results are considered robust, given that the trial subjects had undergone a median of four prior lines of therapy.

• Median progression-free survival (PFS) and overall survival (OS) were not reached after a follow-up period exceeding 36 months.

Safety Profile and Manufacturing

• Safety: The therapy was generally well-tolerated, with no reported deaths, Grade 4 or higher infections, or dose-limiting toxicities.

• Cytokine Release Syndrome (CRS): Approximately 62% of recipients experienced CRS, but most cases were Grade 1, with only one case of Grade 2 (the milder end of the severity spectrum).

• Neurotoxicity: No cases of neurotoxicity, another recognized adverse event with CAR-Ts, were reported.

• Outpatient Potential: The drug’s safety profile suggests it may be suitable for outpatient administration.

• FasTCAR Technology: AZD0120 utilizes Gracell’s FasTCAR platform, which enables the therapy to be manufactured in days, a significant speed advantage over other CAR-Ts that typically require weeks of production time.

In addition to multiple myeloma, AZD0120 is also being tested in clinical trials for the autoimmune disorder systemic lupus erythematosus (SLE) and amyloid light chain (AL) amyloidosis.

Source: https://pharmaphorum.com/news/ash-astrazenecas-dual-wielding-car-t-shows-promise

The pharmaceutical companies Crescent Biopharma (US-based) and Kelun-Biotech (China-based) have announced a strategic partnership to exchange licensing rights for two of their respective oncology drug candidates. This double deal is set to pave the way for clinical trials expected to begin next year.

The partnership involves two separate financial transactions:

1. Rights to SKB105 (ADC): Kelun-Biotech is licensing the rights for its integrin beta-6 (ITGB6)-directed ADC(antibody-drug conjugate) to Crescent Biopharma for research, development, manufacturing, and commercialization in the US, Europe, and all other markets outside of Greater China.

   • Crescent will make an upfront payment of $80 million to Kelun, plus up to $1.25 billion in potential development and commercial milestone payments.

2. Rights to CR-001 (Bispecific Antibody): Kelun-Biotech will acquire the rights to research, develop, manufacture, and commercialize Crescent’s PD-1 x VEGF bispecific antibody (CR-001) within the Greater China region.

   • Kelun will pay Crescent $20 million upfront, along with milestones totaling $30 million.

Both licensing agreements include future royalties payable on net sales of the two products should they successfully reach the market.

Clinical Outlook

• A global Phase I/II trial of CR-001 in patients with solid tumors is anticipated to commence in Q1 2026.

• A Phase I/II clinical trial for SKB105 in patients with solid tumors is expected to start around the same timeframe.

• CR-001 is expected to potentially enhance the effectiveness of combination therapies, such as the co-administration of ADCs.

Context of East-West Collaboration

This agreement is the latest example in a strong trend of partnerships between Western pharmaceutical firms and Chinese biotechs. Analysis indicates that licensing deals between US and Chinese biopharma companies reached record highs last year, representing a 280% increase since 2020. Currently, China-based companies are responsible for 20% of drugs in development globally, underscoring the country’s growing influence in the pharmaceutical sector.

(ORLANDO) – At an American Society of Hematology (ASH) meeting, the pharmaceutical company Eli Lillypresented results from a critical head-to-head study, comparing its drug Jaypirca (pirtobrutinib) against Imbruvica(ibrutinib) from AbbVie and Johnson & Johnson. Both medications are BTK inhibitors, indicated for leukemia and lymphoma.

Efficacy and Response Rates

The Bruin-CLL-314 trial examined Jaypirca versus Imbruvica in patients with chronic lymphocytic leukemia (CLL)or small lymphocytic lymphoma (SLL), spanning both treatment-naïve (first-line) and previously treated populations whose disease had progressed.

• In terms of response: The analysis demonstrated that Jaypirca met its primary objective of non-inferioritycompared to Imbruvica.

  • Across the total of 662 participants, 87% of patients on Jaypirca showed a response, compared to 79% of those on Imbruvica.

  • In the previously treated group (who had progressed/not responded to earlier therapy), the response rate for Jaypirca was 84%, exceeding Imbruvica’s 75%, which was statistically significant for non-inferiority.

  • Among the treatment-naïve participants, Jaypirca recipients had a 93% response rate versus 86% for Imbruvica; however, this difference was not deemed statistical proof of non-inferiority.

Safety and Disease Progression Benefits

• Disease Progression: An interim analysis indicated that Jaypirca shows signs of delaying disease progression or death (Progression-Free Survival). Specifically, the drug reduced the relative risk of these events by 43% in the broad population, with benefits being more pronounced in the treatment-naïve group.

• Safety Profile: While both drugs had similar rates of common side effects (like infections, anemia, gastrointestinal issues), Jaypirca was associated with lower rates of hypertension and irregular heartbeat. These particular side effects have historically impacted the uptake of Imbruvica.

Implications for Market Position

Jaypirca, which recently received conversion of its approval to a traditional nod for use earlier in the treatment landscape for patients who have progressed on a prior BTK inhibitor, is poised to challenge existing therapies.

• The data from the Bruin-CLL-314 trial strengthens Lilly’s argument to position the drug in the earlier lines of care.

• Researchers noted that Jaypirca’s favorable safety profile could particularly benefit older and more frail patients in the first-line setting. However, they also stated that continued, longer follow-up data will be necessary to fully confirm the benefits and determine which patient subgroups are most appropriate for initial treatment with Jaypirca.

Source: https://www-biopharmadive-com.translate.goog/news/ash-2025-lilly-jaypirca-imbruvica-leukemia-lymphoma/807232/?_x_tr_sl=en&_x_tr_tl=vi&_x_tr_hl=vi&_x_tr_pto=tc

Alexion Pharmaceuticals, the rare disease unit of AstraZeneca, has expanded its partnership with biotech company Neurimmune by licensing a second drug candidate. The new agreement involves NI009, a monoclonal antibody in advanced preclinical development, with a total potential value reaching up to $780 million.

Deal Structure and Funding:

In exchange for exclusive worldwide rights to NI009, Alexion is responsible for a combination of an upfront payment and potential payments tied to clinical development, regulatory milestones, and commercialization goals.

NI009 is designed to target and clear lambda light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis. The biotech partner will oversee the first clinical trial of the drug before transitioning the development and commercialization process entirely to Alexion. Should the drug successfully reach the market, the biotech company will also be eligible for tiered royalties on net sales worldwide.

AL amyloidosis is a rare, progressive disorder caused by the build-up of toxic amyloid proteins produced by faulty plasma cells. These deposits, primarily in the heart and kidneys, lead to severe organ damage and dysfunction.

Post-Challenge R&D Strategy

This latest deal follows the partners’ initial collaboration four years ago in 2022, which licensed the ATTR amyloidosis candidate NI006. Subsequently, Phase 1 data for NI006 showed substantial reductions in cardiac amyloid deposition at higher doses.

However, AstraZeneca has faced challenges with its existing AL amyloidosis candidate, anselamimab. In July of this year, the Phase 3 CARES study for anselamimab failed to meet its primary endpoint of reducing deaths and hospitalizations.

A spokesperson for Alexion stated that they plan to apply key learnings derived from the CARES program to the development of NI009. The goal is to develop a complementary fibril depleter, potentially capitalizing on NI009’s broad activity against diverse lambda light chain subtypes – a feature noted by Neurimmune’s CEO as significant despite the high clonal heterogeneity of the disease. This expanded partnership reinforces the corporation’s commitment to delivering new therapies that may improve survival and cardiac outcomes for patients with AL amyloidosis.

Source: https://www.fiercebiotech.com/biotech/astrazenecas-latest-amyloidosis-pact-neurimmune-could-reach-780m

A therapeutics company has announced a funding agreement worth $275 million with a financial fund specializing in pharmaceutical royalties. The company’s stock gained 5.84% following the news.

The deal is centered on the future net sales of tividenofusp alfa, the company’s lead drug candidate. This is an investigational TransportVehicle-enabled enzyme replacement therapy designed to cross the blood-brain barrier to treat mucopolysaccharidosis type II (MPS II), commonly known as Hunter syndrome.

Transaction Details and Payment Conditions

The funding agreement is contingent upon various closing conditions, including the accelerated approval of tividenofusp alfa by the U.S. Food and Drug Administration (FDA).

• Initial Payment: The financial fund will make an initial payment of $200 million upon the transaction closing (pending FDA accelerated approval).

• Additional Payment: The fund is required to make an additional payment of $75 million if the therapeutics company obtains European Medicines Agency (EMA) approval for tividenofusp alfa by December 31, 2029.

In exchange for these payments, the financial fund will receive a 9.25% royalty on the worldwide net sales of tividenofusp alfa from the therapeutics company. Royalty payments will cease upon reaching a multiple of 3.0x, or 2.5x if achieved by the first quarter of 2039.

Regulatory Status of Hunter Syndrome Drug

The Biologics License Application (BLA) seeking accelerated approval for tividenofusp alfa is currently under FDA review. However, the target action date was extended from January 5 to April 5, 2026. This extension followed the company’s submission of updated clinical pharmacology information in response to an FDA request. The company stated that the submission was unrelated to efficacy, safety, or biomarkers.

The FDA classified the submission as a major amendment to the BLA, leading to the extension of the target action date. Nevertheless, the regulatory body did not request any additional trial data.

Tividenofusp alfa had previously been granted key FDA designations, including Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease. If approved, it may become the first Hunter syndrome therapy designed to address both the cognitive and physical manifestations of the disorder.

Other Pipeline Candidates

The therapeutics company is also developing other drug candidates through collaborations with major partners:

• Frontotemporal Dementia (FTD-GRN): In collaboration with Takeda to develop DNL593. A Phase I/II study is ongoing.

• Parkinson’s Disease (PD): Continues co-development of BIIB122 with Biogen. The Phase IIb LUMA study is fully enrolled, with a readout expected in 2026. Additionally, the company is conducting the Phase IIa BEACON study, which specifically enrolls participants with LRRK2-associated PD to assess LRRK2 inhibition.

Source: https://finance.yahoo.com/news/denali-enters-275m-funding-deal-145600216.html

A therapeutics company has announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial, evaluating the efficacy of Deramiocel – an investigational cell therapy for Duchenne Muscular Dystrophy (DMD). This outcome offers new hope for the community affected by this rare and debilitating disease.

Superior Efficacy Across Both Skeletal Muscle and Cardiac Functions

According to the company’s announcement, the HOPE-3 trial successfully met both its pre-specified primary objectives with clear statistical significance. Specifically:

• Regarding skeletal muscle function: Deramiocel therapy demonstrated a nearly 54% slowing of skeletal muscle disease progression compared to the placebo group, as measured by the Performance of Upper Limb (PUL v2.0) score. This is a crucial finding for patients, especially those who have lost ambulation.

• Regarding cardiac function: The study also showed a significant preservation of left ventricular ejection fraction (LVEF%) over 12 months in patients treated with Deramiocel, compared to the placebo group. Cardiomyopathy is a leading cause of mortality in DMD patients, making the ability to preserve cardiac function immensely significant in improving long-term prognosis.

Prospects for FDA Approval Process

Based on the impressive results from the HOPE-3 trial, the company plans to promptly submit this data to the U.S. Food and Drug Administration (FDA). This data will serve as a response to the Complete Response Letter issued by the FDA in July 2025. The company expressed confidence that the HOPE-3 results are robust enough to meet FDA requirements and support regulatory review for approval under current guidelines.

Critical Significance for the Duchenne Community

These topline results from HOPE-3 bring great hope to the Duchenne Muscular Dystrophy community, particularly for non-ambulatory individuals – a patient group with very limited effective treatment options. The prospect of a therapy that can slow the decline in upper limb function and preserve cardiac function is incredibly valuable, offering more time and improving the quality of life for those living with Duchenne.

Experts are eagerly awaiting the full results of the trial and anticipate continuous progress in developing new therapeutic options for families facing this condition.

Source: https://www.capricor.com/investors/news-events/press-releases/detail/331/capricor-therapeutics-announces-positive-topline-results